Novan (NASDAQ: NOVN) is one of 19 public companies in the “Specialty & Advanced Pharmaceuticals” industry, but how does it contrast to its competitors? We will compare Novan to related companies based on the strength of its dividends, institutional ownership, profitability, earnings, risk, valuation and analyst recommendations.

Analyst Recommendations

This is a summary of current recommendations and price targets for Novan and its competitors, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Novan 0 1 3 0 2.75
Novan Competitors 98 367 965 28 2.63

Novan currently has a consensus price target of $17.24, indicating a potential upside of 173.69%. As a group, “Specialty & Advanced Pharmaceuticals” companies have a potential upside of 23.75%. Given Novan’s stronger consensus rating and higher possible upside, analysts plainly believe Novan is more favorable than its competitors.

Earnings and Valuation

This table compares Novan and its competitors gross revenue, earnings per share and valuation.

Gross Revenue EBITDA Price/Earnings Ratio
Novan $768,999.00 -$49.04 million -0.79
Novan Competitors $2.40 billion $905.93 million 3.12

Novan’s competitors have higher revenue and earnings than Novan. Novan is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.


This table compares Novan and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Novan N/A -194.61% -99.61%
Novan Competitors -538.85% -41.85% -24.81%

Institutional and Insider Ownership

6.1% of Novan shares are owned by institutional investors. Comparatively, 66.4% of shares of all “Specialty & Advanced Pharmaceuticals” companies are owned by institutional investors. 10.7% of Novan shares are owned by insiders. Comparatively, 10.0% of shares of all “Specialty & Advanced Pharmaceuticals” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.


Novan competitors beat Novan on 6 of the 11 factors compared.

Novan Company Profile

Novan, Inc. is a late-stage pharmaceutical company. The Company is engaged in the development and commercialization of therapies using its nitric oxide platform. The Company develops product candidates using its Nitricil technology, which enables the Company to engineer tunable new chemical entities (NCEs). The Company’s formulation science enables it to further tune the release of nitric oxide when applied to the skin by using the combinations of inactive ingredients. It is developing SB204 for the treatment of acne vulgaris in Phase III. The Company is developing its product candidate, SB206, for the treatment of external genital and perianal warts in Phase II. It is developing SB208, an investigational topical anti-fungal for the treatment of fungal infections of the skin and nails. It is developing SB204 for the treatment of inflammatory skin diseases. Its pipeline also includes SB414, a topical cream product candidate.

Receive News & Stock Ratings for Novan Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novan Inc and related stocks with our FREE daily email newsletter.